Amoéba Logo

Amoéba

Develops amoeba-based natural fungicides for agriculture and active ingredients for cosmetics.

ALMIB | PA

Overview

Corporate Details

ISIN(s):
FR0011051598 (+2 more)
LEI:
9695005QNE7C8Z0LXU64
Country:
France
Address:
38 AVENUE DES FRERES MONTGOLFIER, 69680 CHASSIEU
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Amoéba is a greentech company that develops and commercializes solutions for managing microbiological risk based on the patented use of a biological agent derived from the amoeba *Willaertia magna*. The company's primary focus is on two key global markets: agricultural biocontrol and cosmetics. For the plant protection sector, its technology offers a natural, fungicidal alternative to chemical treatments against diseases like mildew and rust. For the cosmetics industry, it provides a natural active ingredient. Amoéba's technology has also shown potential applications in water treatment and wound care. Founded in 2010, the company is transitioning from research and development to an industrial and commercial-scale entity.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-20 18:30
Regulatory News Service
AXPERA named biocontrol solution of the year 2025 // Amoeba's anti-fungal innov…
English 388.0 KB
2025-10-20 18:30
Regulatory News Service
AXPERA désignée solution de biocontrôle de l'année 2025 // L'innovation anti-ma…
French 414.4 KB
2025-07-22 18:25
Share Issue/Capital Change
Amoéba launches a capital increase open to all to support its industrial and co…
English 418.9 KB
2025-07-22 17:45
Regulatory News Service
Amoéba signs an agreement with Metron Technology, a subsidiary of Oriental Beau…
English 348.1 KB
2025-07-22 17:45
M&A Activity
Amoéba signe un accord avec Metron Technology, filiale du groupe Oriental Beaut…
French 345.8 KB
2025-06-17 18:00
Regulatory News Service
Amoéba takes another decisive step forward with the final approval of its bioco…
English 391.5 KB
2025-06-17 18:00
Regulatory News Service
Amoéba franchit une nouvelle étape décisive avec l'approbation définitive de sa…
French 387.4 KB
2025-06-03 17:45
Regulatory News Service
Koppert et Amoéba signent un accord de distribution majeur pour une solution bi…
French 191.6 KB
2025-06-03 17:45
Regulatory News Service
Koppert and Amoéba sign major distribution agreement for innovative biofungicid…
English 170.4 KB
2025-05-22 18:00
Report Publication Announcement
Amoéba: Ordinary and Extraordinary General Meeting of 26 June 2025
English 332.5 KB
2025-05-22 18:00
Pre-Annual General Meeting Information
Amoéba : Assemblée Générale Ordinaire et Extraordinaire du 26 juin 2025
French 331.8 KB
2025-05-21 18:00
Regulatory News Service
A new milestone towards the market launch of AXPERA: EU Member States unanimous…
English 375.5 KB
2025-05-21 18:00
Regulatory News Service
Nouvelle étape franchie vers la mise sur le marché d'AXPERA : vote à l'unanimit…
French 372.5 KB
2025-05-20 19:00
Board/Management Information
Amoéba announces the nomination of Charlotte Franceries, a leading figure in th…
English 339.5 KB
2025-05-20 19:00
Board/Management Information
Amoéba annonce l'arrivée au sein de son Conseil d'administration de Charlotte F…
French 352.3 KB

Automate Your Workflow. Get a real-time feed of all Amoéba filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Amoéba

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Amoéba via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-30 N/A Other Buy 6,300 3,609.90 EUR
2024-08-29 N/A Other Sell 5,500 3,564.00 EUR
2024-08-28 N/A Other Buy 3,200 1,782.08 EUR
2024-08-27 N/A Other Buy 20,049 11,231.45 EUR
2024-08-26 N/A Other Buy 31,107 17,441.69 EUR
2024-08-22 N/A Other Buy 2,255 1,298.88 EUR
2024-08-20 N/A Other Buy 16,664 8,838.59 EUR
2024-08-19 N/A Other Buy 13,390 6,795.43 EUR
2024-08-16 N/A Other Buy 6,745 3,468.28 EUR
2024-08-09 N/A Other Buy 40,748 21,559.77 EUR

Peer Companies

Company Country Ticker View
DexTech Medical AB Logo
Developing pharmaceuticals for urological oncology using its proprietary GuaDex technology platform.
Sweden DEX
DG INNOVATE PLC Logo
Develops sustainable tech for EV drivetrains and next-gen energy storage materials.
United Kingdom DGI
Dicot Pharma AB Logo
Developing next-gen potency drugs for erectile dysfunction and premature ejaculation.
Sweden DICOTBT
Israel DNA
Elanix Biotechnologies AG Logo Germany ELN
E-Novia Logo
A deep-tech factory building Physical AI ventures for mobility, logistics, and automation.
Italy E9IA
EUROESPES Logo
Research & patient care for CNS diseases via personalized genomic medicine.
Spain EEP
Eurofins-Cerep Logo
CRO offering preclinical drug profiling, screening & pharmacology testing for pharma/biotech.
France ALECR
Evotec SE Logo
A drug discovery and development partner for pharma, biotech, and academia.
Germany EVT
FARON PHARMACEUTICALS OY Logo
Develops myeloid cell-targeting immunotherapies for solid and hematological cancers.
Finland FARN

Talk to a Data Expert

Have a question? We'll get back to you promptly.